Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2026 11:08 ET | Source: Foundation for Sarcoidosis Research

FSR Announces $400,000 Investment in New Round of Cardiac and Pilot Grant Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis

FSR Invests in New Round of Research Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis
January 20, 2026 10:38 ET | Source: Orphai Therapeutics Inc.

Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with...
January 15, 2026 11:46 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Announces New Members to the Expanding FSR Global Sarcoidosis Clinic Alliance, Including Its First International Member

Foundation for Sarcoidosis Research welcomes clinics to Global Sarcoidosis Clinic Alliance.
December 18, 2025 14:20 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Publishes Comprehensive Voice of the Patient Report Following Externally Led PFDD Meeting with the FDA

The FSR Voice of the Patient report outlines a clear path forward for drug developers, researchers, clinicians, and regulators for sarcoidosis.
November 25, 2025 08:55 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Convenes Global Leaders for Landmark Clinic Alliance Meeting and Sarcoidosis Biomarker Summit

FSR convened more than 40 global clinicians and researchers in Chicago for inaugural sarcoidosis meetings.
October 06, 2025 10:36 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Celebrates 25 Years of Innovation, Empowerment, and Progress at Anniversary Awards Gala

FSR celebrates 25th anniversary in the fight against sarcoidosis with awards gala in Chicago.
September 30, 2025 05:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society Congress 2025
September 17, 2025 10:01 ET | Source: Foundation for Sarcoidosis Research

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results

Foundation for Sarcoidosis Research acknowledges results of aTyr Pharma’s Phase 3 trial of efzofitimod in pulmonary sarcoidosis.
September 15, 2025 07:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
July 22, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis